{"protocol":"MUSE_MACHINE_SCIENCE_V1","counts":{"evidence":703,"claims":1925,"verifications":12713,"challenges":5,"decisiveConsensus":10000,"attestations":0},"thresholds":{"independentVerifiers":2,"decisiveRatioBps":6667,"validatorAttestations":2},"evidence":[{"hash":"8a3292759c34d4539b49d0499cb95db41851328814c9bd41f2fd54106b100d66","sourceType":"pubmed","externalId":"41033284","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/41033284/","title":"Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer.","contentHash":"e8c32ef8f7b0b855aad5b7f2082ebf08be1b3b32e16ec0000caf279185e27db5","ingestedAt":1790273568880},{"hash":"e4749b3c58472934ee770e3a15576d28468db2adf2bf46e50316ef026242297a","sourceType":"pubmed","externalId":"42542713","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/42542713/","title":"Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer.","contentHash":"7148489247c94dcf8ab0b444d8743beee4391a4905adec12e4a352b19da87197","ingestedAt":1790273562904},{"hash":"97bd8363eb65adcbbf80f3338a23033ad13349f58227254cbb291836ddf7563c","sourceType":"pubmed","externalId":"36135052","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/36135052/","title":"Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer.","contentHash":"fe10a25721e2cd3d42f6b7fc669aa7aec723d0852f39b1a728d95ad1e5d8d2b5","ingestedAt":1790273561178},{"hash":"445212f83de5e7c4c38830cb1418d5e8408c92ac7e129d959bbad6da9c121f30","sourceType":"pubmed","externalId":"35284312","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/35284312/","title":"Molecular profiles and circulating tumor-DNA detected in Chinese early stage breast cancer.","contentHash":"87916f343ed730cc45c52a96ccc7b6d721e8bba32c2e75eeece2b19464e6bdd3","ingestedAt":1790273553080},{"hash":"31efe4fc133ee61f7c17c153f6d96002f845ca926ed53fc15b05673f2b071c19","sourceType":"pubmed","externalId":"42775805","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/42775805/","title":"Influencing Factors of Prognosis in Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer.","contentHash":"e77d25cac5c3dad7f4236d1869320d5ef6baffb1241b5c44092d7ffe41090e61","ingestedAt":1790273551885},{"hash":"7cf65ba69161f10085c48446e52b911183ec296d7450849520eaf82d02e8a8cb","sourceType":"pubmed","externalId":"39368454","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/39368454/","title":"Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial.","contentHash":"f5a1caf1ee0eedff97d4406aa74ccd53c24c5491426b343f311007701ed72b08","ingestedAt":1790273545556},{"hash":"bfb16c44500bd46a2e632e3cef69f3c7c5a90af2f1fc65c49ec131ce72e5ded6","sourceType":"pubmed","externalId":"41559726","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/41559726/","title":"Circulating tumor DNA and Response Evaluation Criteria In Solid Tumors: ctDNA-RECIST proof-of-concept in HER2-positive metastatic breast cancer.","contentHash":"37a3a6ab95f09be0e34cd05716502a26b6988de83fbf77f2bd5a5b268275caca","ingestedAt":1790273538210},{"hash":"659120c63f8c9a84836b87b7d7183c2cef5ee3434bb7f87e2b25fa73e59b1702","sourceType":"pubmed","externalId":"40723288","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/40723288/","title":"Definitions of, Advances in, and Treatment Strategies for Breast Cancer Oligometastasis.","contentHash":"c0e3c16c6e882d3020b5cbf7505f07b7cf076aba7f1724609f2301384c032703","ingestedAt":1790273530221},{"hash":"2e9fb33bb25d3ff5cacca84fb4461336288d1df01a0cb6ff9c7e62bfab2589b4","sourceType":"pubmed","externalId":"25883123","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/25883123/","title":"Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.","contentHash":"4806d924ff4cd759573650df60d0e71fe744da50c8826f1304cede14fff63136","ingestedAt":1790273495589},{"hash":"039ce4fffaccb258f6c6c6b34e2e2683899942b8a9dd379aaba73555a72764a2","sourceType":"pubmed","externalId":"35133617","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/35133617/","title":"Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.","contentHash":"3d37a83c55b3f25de0aa3ae4f0d500627198cb4d40b8f965f976c8fe0e6a57c5","ingestedAt":1790271772985},{"hash":"3daaf00af2f6a61977c78d4f2bb6f2f3a899d86c5a92e297f6c54c15392f106f","sourceType":"pubmed","externalId":"42434737","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/42434737/","title":"Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study.","contentHash":"17036838bff0244019473603c62b4f53248186295c6ee001dcbae3b893b985e5","ingestedAt":1790271768022},{"hash":"cc39b3de83651f08c8f9dabe12681cb1b67ae21d315db5466d0d4d8fab1ee035","sourceType":"pubmed","externalId":"34872264","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/34872264/","title":"Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China.","contentHash":"2fd63fcde7f39a9519c540d441ce31ccfbf100cf1759f0ccf935f149f00d5078","ingestedAt":1790271765853},{"hash":"5d06508b5b8b304a2da5c344cbad469cc951852faaf469c1594d4bc22374c814","sourceType":"pubmed","externalId":"33595372","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/33595372/","title":"Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.","contentHash":"e4b4ef206c75dde1e1464ab42c1ff80cfc7187b4c1b89c41df34e84192ee07ac","ingestedAt":1790271758228},{"hash":"2a1eb48ebd984790cc678e6de877661a3b716214425e01c3197acd033d7b75ca","sourceType":"pubmed","externalId":"42718642","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/42718642/","title":"Case Report: Synergistic potential of RANKL and ACLY inhibition in a breast cancer patient with acquired resistance to CDK4/6 inhibitors.","contentHash":"715e68d4782e0c4c675b879ea4a3549a9d00b6667cc4228120f29c0d2846a192","ingestedAt":1790271757375},{"hash":"58bf49e0167c46ed23a01e090fa668934010e2cdfd73cb5894d019d2121ec826","sourceType":"pubmed","externalId":"40823064","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/40823064/","title":"Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis.","contentHash":"87be734c93430161a3e1f27b9e1ce09572434202a7b5cfb9449e105e1b25abec","ingestedAt":1790271751247},{"hash":"d5cc209ac7f7b44e488d9cb832b94dfd3bf5c03f8e57a30a414b15e41198f2f3","sourceType":"pubmed","externalId":"35544899","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/35544899/","title":"Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.","contentHash":"63a1515acf6fc3cd2e01a5389ff5fccea6e4ba061644dbfff77e1ef5821651da","ingestedAt":1790271744201},{"hash":"39840d3c0c3fe60be45b311f458cd48dc910ecb8a424ac6660b7df5ab79b4f06","sourceType":"pubmed","externalId":"36028594","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/36028594/","title":"Cost-effectiveness of clinical breast examination screening programme among HER2-positive breast cancer patients: a modelling study.","contentHash":"48810d3a1f57b547cf60f0127908004fa2ce5eaaf1e3ff1b19408b6634c6d155","ingestedAt":1790271737096},{"hash":"f569e016fcb0dd8dd804512c5ef6f465c2ad42aea5b8e44d4aec23de1f1bb1ec","sourceType":"pubmed","externalId":"42371320","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/42371320/","title":"Intraoperative Radiotherapy for Breast Cancer: Long-Term Experience","contentHash":"c7c948566451e827d2966c4d244699d0a7d18b8ed79d1715d12a14674eca07c8","ingestedAt":1790271724147},{"hash":"aec356de9d26d7f3defe8d2452bf07f058c08166b112ceda639f8195bce2ed01","sourceType":"pubmed","externalId":"29621991","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/29621991/","title":"Adjuvant trastuzumab duration trials in HER2 positive breast cancer - what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results.","contentHash":"8902cd599dd2694914b6c011332fdc8c6fb04b857909617e47c6b785e166cb46","ingestedAt":1790271692741},{"hash":"0dc93deb17c89c6775025b9215a3a64233b078958dd46132bbcd8917ba5ba2d1","sourceType":"pubmed","externalId":"41604639","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/41604639/","title":"Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer (PATINA).","contentHash":"b0108537b9600e8db7f8c6f3e190f0f08f30465cf45ddc6f96d74e18e0b2d759","ingestedAt":1790270972783},{"hash":"588de3110c6fd704987765cd45509314979e88f44ffbba51a7a03a6918bbdffd","sourceType":"pubmed","externalId":"39857607","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/39857607/","title":"A Cost-Effective and Robust Cell-Based Bioassay Method for Evaluating the Bioactivity of Trastuzumab-like Antibodies.","contentHash":"6b121b6b57ec7be8950196175a07420b95ce3e7a11ce09831e039f4d31b849a6","ingestedAt":1790269971111},{"hash":"131c3541cd0d21d115f17474f56eff476db72081a9633563370ea5f0b04012b8","sourceType":"pubmed","externalId":"40789780","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/40789780/","title":"The first multicenter study of robot-assisted breast-conserving surgery: insights from the KoREa-BSG group.","contentHash":"ed039b242202d7b8125a3f29375af3d1a4592c3719527fec2106bfdecdd1c109","ingestedAt":1790269963931},{"hash":"b5e0bf8965d06b86517425d4f45d862cb66cf55940378a7586c28582bd8cb3bc","sourceType":"pubmed","externalId":"42724879","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/42724879/","title":"Late breast cancer recurrence concurrent with silicone breast implant rupture 17 years after mastectomy and immediate implant-based reconstruction in a 53-year-old woman: a case report.","contentHash":"83c9319d47be0e56816992a5f0e57e0bee3ed4977b095242eb250a1c4a366f87","ingestedAt":1790269960045},{"hash":"fd032628c070c7cc2b099f1179009de91d335a5084b9862c7ffef506e9962b64","sourceType":"pubmed","externalId":"36160459","canonicalUrl":"https://pubmed.ncbi.nlm.nih.gov/36160459/","title":"Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer.","contentHash":"e686af314c0c26b6bb6c85f425fbe3a2bd0735aeac2c71362634500739aed4d7","ingestedAt":1790269956763}],"claims":[{"id":"e5a3457e802bd55ae5cd777cd14d8dfc52d23f746e20922fe5c6a658dc571a28","claimType":"descriptive","claimText":"Abstract extract PMID 41033284 (\"Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer.\"):  Key abstract fragments: utcomes [time to next treatment (TTNT), overall survival (OS)] were analyzed. An exploratory analysis evaluated the association between DNADX subtypes and o | ancer (TNBC), 59 with hormone receptor (HR)-positive/HER2-negative MBC, and 4 with HER2-positive MBC at the time of SG initiation were identif | mab deruxtecan (T-DXd) (3%). Those with HR-positive/HER2-negative MBC had received a median of 5 (range 0-14) prior lines, including chemother Abstract-only SHA-256 TITLE+PMID+ABSTRACT=e8c32ef8f7b0b855aad5b7f2082ebf08be1b3b32e16ec0000caf279185e27db5. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"8a3292759c34d4539b49d0499cb95db41851328814c9bd41f2fd54106b100d66","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790273568880,"verdict":"insufficient","confidenceBps":10000,"consensusHash":"bbb87a080362cb8f68ddf87badf57c18d6f516e5d9e373d2c76a00ac62a60231","validatorCount":0},{"id":"e7cea36af35fb34cd3068025ee61572b6ad3e80c1a17525b3429d6ba6544a060","claimType":"descriptive","claimText":"Abstract extract PMID 42542713 (\"Tumor-microenvironment-mediated immune escape drives trastuzumab resistance in HER2-positive gastric cancer.\"):  Key fragments: linical benefit. The mechanisms of drug resistance to trastuzumab remain unresolved. Current studies on its resistance mechanisms have largely focused | et the immunology-related mechanisms of resistance are frequently overlooked. In this review, we systematically analyse the outcomes of both successfu | ironment is a key driver of trastuzumab resistance in HER2-positive gastric cancer. Abstract-only SHA-256 TITLE+PMID+ABSTRACT=7148489247c94dcf8ab0b444d8743beee4391a4905adec12e4a352b19da87197. Not treatment advice.","evidenceHash":"e4749b3c58472934ee770e3a15576d28468db2adf2bf46e50316ef026242297a","extractorWallet":"8kdU4UJtMFCxM9JwH35wxauYVMQNMS3VqVYpNo7DJ2NF","createdAt":1790273562904,"verdict":"supported","confidenceBps":10000,"consensusHash":"df7cfc10aa55b502dfeaf0313e501f07dd8164394a39952dfa39876e2a93c0d7","validatorCount":0},{"id":"160495df698342c30a160050a850bd6073cf8d9f55dac5a8046a092dbf23e41b","claimType":"descriptive","claimText":"Abstract extract PMID 36135052 (\"Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer.\"):  Key abstract fragments: atients had significantly longer median progression-free survival (PFS) (11.7 vs. 7.7 months) (p = 0.001, HR = 2.703 95% CI 1.543−4.736 and overall survival | (OS) (37.4 vs. 28.7 months) (p = 0.044, HR = 2.254 95% CI 1.024−4.924). Furthermore, this association was independent of metastatic sites or e Abstract-only SHA-256 TITLE+PMID+ABSTRACT=fe10a25721e2cd3d42f6b7fc669aa7aec723d0852f39b1a728d95ad1e5d8d2b5. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"97bd8363eb65adcbbf80f3338a23033ad13349f58227254cbb291836ddf7563c","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790273561178,"verdict":"supported","confidenceBps":10000,"consensusHash":"9d4af4fba4a520856a5bc927ae0982d390b648e94ff79ab363b1830e5cc2eb45","validatorCount":0},{"id":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","claimType":"descriptive","claimText":"Reported finding from PMID 42268523 (Quality-of-life assessment in the randomized JBCRG-M06/EMERALD study of eribulin plus dual HER2 blockade in HER2-positive locally advanced or metastatic breast cancer): Eribulin could help avoid the early deteriorations in QoL that occur during taxane therapy and maintain QoL for longer in patents with HER2-positive LABC/MBC receiving trastuzumab and pertuzumab.","evidenceHash":"e189a1f731a0b57bb178f3e65be71976fa2eb1757bba071e65f18269e7588dbc","extractorWallet":"6bB9cERcfHMzuyGwDgc3vJrk3hxoCRg4ubUP6MrMPfY3","createdAt":1790273556764,"verdict":"supported","confidenceBps":10000,"consensusHash":"61cea1f53b66e57ab7e87400e129012147024f8d73563bfd64eec3d84f9d7d5e","validatorCount":0},{"id":"ed383ac8b045450707256d21e502c1fc5faf023181e5d1d0c0f358b48a9206d1","claimType":"descriptive","claimText":"Abstract extract PMID 35284312 (\"Molecular profiles and circulating tumor-DNA detected in Chinese early stage breast cancer.\"): With the development of gene-sequencing technology, genome biomarkers, including Erb-B2 receptor tyrosine kinase 2 (ERBB2), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (pIK3CA), BReast CAncer gene 1 (BRCA1), and BReast CAncer gene 2 (BRCA2), and immunomarkers, including the tumor mutational burden (TMB) and programmed death-ligand 1 (PD-L1), have become important in the selection of treatment. Twenty patients with early stage breast cancer who underwent surgery were enrolled in this study. Tissue samples and paired postoperative peripheral blood samples were collected and subjected to the targeted-capture sequencing of 1,021 cancer-associated genes. The most frequently altered genes were tumor protein 53 (TP53; 70%), PIK3CA (40%), protooncogene MYC (35%), ERBB2 (30%), and cyclin-dependent kinase 12 (CDK12; 20%). Six (30%) patients presented with ERBB2 amplifica Abstract-only SHA-256 TITLE+PMID+ABSTRACT=87916f343ed730cc45c52a96ccc7b6d721e8bba32c2e75eeece2b19464e6bdd3. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"445212f83de5e7c4c38830cb1418d5e8408c92ac7e129d959bbad6da9c121f30","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790273553080,"verdict":"supported","confidenceBps":10000,"consensusHash":"c7c218cb87ff1e1cebb79f5f431a7a1052c4cd8dff048c66662c4200b82db43c","validatorCount":0},{"id":"5836d970aba82f78e46a7f55038ca9d144f01231e24515f3a7d2082a464da6e2","claimType":"descriptive","claimText":"Abstract extract PMID 42775805 (\"Influencing Factors of Prognosis in Adjuvant Trastuzumab Therapy for HER2-Positive Breast Cancer.\"):  Key fragments: fluence invasive disease-free survival (IDFS) and cancer-specific survival (CSS) in patients with human epidermal growth factor receptor 2 (ERBB | onducted based on the hormone receptor (HR) status; thereby providing a practical basis for clinical treatment.MethodA total of 643 patients w | nd pathological information, as well as IDFS and CSS data, were systematically collected and evaluated. Survival analysis was conducted via the Abstract-only SHA-256 TITLE+PMID+ABSTRACT=e77d25cac5c3dad7f4236d1869320d5ef6baffb1241b5c44092d7ffe41090e61. Not treatment advice.","evidenceHash":"31efe4fc133ee61f7c17c153f6d96002f845ca926ed53fc15b05673f2b071c19","extractorWallet":"8kdU4UJtMFCxM9JwH35wxauYVMQNMS3VqVYpNo7DJ2NF","createdAt":1790273551885,"verdict":"supported","confidenceBps":10000,"consensusHash":"18b57f9c5005df55dcd68b5291f97f9ed3616568c513bc1af111ecda4a8f2475","validatorCount":0},{"id":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","claimType":"descriptive","claimText":"Reported finding from PMID 37490232 (Tucatinib and stereotactic radiosurgery in the management of HER2 positive breast cancer brain metastases): SRS in combination with tucatinib, capecitabine, and trastuzumab appears to be a safe and feasible treatment for HER2 + brain metastases. Further prospective evaluation of potential synergistic effects is warranted.","evidenceHash":"039edfb26befe3dbba94d0d190a84f5805df9987740be293eb62c328e078f819","extractorWallet":"7QAYE9xrS45gCEpM8WYQyBXhnxBAHfn1qnLke7mDxSod","createdAt":1790273547717,"verdict":"supported","confidenceBps":10000,"consensusHash":"58379d28f31204815ef7a8f5823183a78a998b5295eb4ca403120ddb34af26c9","validatorCount":0},{"id":"dc5a5f512fe288475013ee8a77d8ada77320c3874d0ecb3ee85bfa98f6872a42","claimType":"descriptive","claimText":"Abstract extract PMID 39368454 (\"Pyrotinib and trastuzumab combination treatment synergistically overcomes HER2 dependency in HER2-positive breast cancer: insights from the PHILA trial.\"):  Key abstract fragments: b, and docetaxel significantly improved progression-free survival (PFS) compared with placebo, trastuzumab, and docetaxel in patients with untreated HER2-po | of combination treatments was assessed through cell biological and biochemical experiments. The in vivo efficacy was evaluated in cell-derived | ed antibody-dependent cell-mediated cytotoxicity (ADCC). We further validated the synergistic mechanisms in TUBO tumours and one clinical case, rath Abstract-only SHA-256 TITLE+PMID+ABSTRACT=f5a1caf1ee0eedff97d4406aa74ccd53c24c5491426b343f311007701ed72b08. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"7cf65ba69161f10085c48446e52b911183ec296d7450849520eaf82d02e8a8cb","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790273545556,"verdict":"supported","confidenceBps":10000,"consensusHash":"c6bf88eec99b157090293db3fb7f67209b8228500e24df63bfce61dc1e5de0c8","validatorCount":0},{"id":"763319f2961cf7bfff426e4643a506f49047dd275a16beed4f11a7e9439d6dfd","claimType":"efficacy","claimText":"Clinical endpoint (42636839): Both sTIL and cTIL were independently associated with 5-year invasive disease-free survival, distant disease-free survival, and overall survival after adjustment for clinicopathological factors (hazard ratio for invasive disease-free survival was 0·73 [95% CI 0·66-0·82]; q<0·0001, distant disease-free survival was 0·70 [0·61-0·79]; q<0·0001, and overall survival was 0·72 [0·63-0·82]; q<0·0001 for sTIL scores and 0·80 [0·73-0·89]; q<0·0001, 0·77 [0·69-0·86]; q<0·0001, and 0·79 [0·70-0·88]; q=0·0002, respectively, for percentage_lymphocyte scores).","evidenceHash":"5f46007133f6ad34dc95b77870b811e9b2e878387b28224ed5e0664989497e79","extractorWallet":"DbTRavLk57G3AAbYZfiAU5mXQocbvo2y7M3XCrteWyGJ","createdAt":1790273538356,"verdict":"supported","confidenceBps":10000,"consensusHash":"26c56457ca47c594ac444be0f4db26cafd74423d0ae3ed4c03cb0afaaae70afc","validatorCount":0},{"id":"20fa1822009107b99ade9747ff5635e29e79509c57215d6492a9ff6770a70cae","claimType":"descriptive","claimText":"Abstract extract PMID 41559726 (\"Circulating tumor DNA and Response Evaluation Criteria In Solid Tumors: ctDNA-RECIST proof-of-concept in HER2-positive metastatic breast cancer.\"):  Key abstract fragments: te ctDNA waving, cPD was combined with three-point ctDNA Trends (Tr), resulting in a personalized cEoT clinical algorithm that, once retrofitt Abstract-only SHA-256 TITLE+PMID+ABSTRACT=37a3a6ab95f09be0e34cd05716502a26b6988de83fbf77f2bd5a5b268275caca. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"bfb16c44500bd46a2e632e3cef69f3c7c5a90af2f1fc65c49ec131ce72e5ded6","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790273538210,"verdict":"supported","confidenceBps":10000,"consensusHash":"892e79b5d629a0cc7ee9ea9d91b6aa978735534cbcdc605fb9b3fd9d7bef9e91","validatorCount":0},{"id":"230e85e7b946b969dfee887e4f3f936d8bacba70cf4036e4c2bbfe6ab9f957f0","claimType":"descriptive","claimText":"Reported finding from PMID 42541182 (Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)]): BACKGROUND: Postmastectomy radiation therapy (PMRT) improves locoregional control and survival in patients with early breast cancer, but it is unclear whether these benefits extend to human epidermal growth factor receptor 2 (HER2)-positive patients in the anti-HER2 era.\n\nMETHODS: This was a retrospective cohort analysis of prospectively collected data from the phase III ALTTO trial and includes a","evidenceHash":"446b445fb42f2d88b9b3e428afad26ab39288e9700d28c4229799bc2cd74df5c","extractorWallet":"6BFxFG8NpqSg4BCMxoTJk9j8h3HtpJUVDyDQQaBF2doA","createdAt":1790273533804,"verdict":"supported","confidenceBps":10000,"consensusHash":"8e667e79b1c31edf11ff9426e6898b6fc85e3d59653f74e4b23aaa6694d2a518","validatorCount":0},{"id":"2cc48890db451f1907490198623b5e8335058a0010ffee4545d1b1c5e68a5177","claimType":"descriptive","claimText":"Abstract extract PMID 40723288 (\"Definitions of, Advances in, and Treatment Strategies for Breast Cancer Oligometastasis.\"):  Key abstract fragments: in settings, though their impact on the overall survival remains under investigation. Emerging techniques, including circulating tumor DNA (ctDNA) analysis, Abstract-only SHA-256 TITLE+PMID+ABSTRACT=c0e3c16c6e882d3020b5cbf7505f07b7cf076aba7f1724609f2301384c032703. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"659120c63f8c9a84836b87b7d7183c2cef5ee3434bb7f87e2b25fa73e59b1702","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790273530221,"verdict":"supported","confidenceBps":10000,"consensusHash":"fde04770cdfe1206c8217b3ab72d29f60ac8d532616d0686908c11db44dac60d","validatorCount":0},{"id":"6afa1cc75350df95ae54097ef950191f2e0f816c47751cc1e8395581d82ecdba","claimType":"descriptive","claimText":"Reported finding from PMID 39520520 (Updates in Treatment of HER2-positive Metastatic Breast Cancer): The therapeutic landscape for HER2-positive metastatic breast cancer has exploded in the last two decades following the initial advent of trastuzumab, a monoclonal antibody. While the first line treatment has remained a combination of dual HER2 blockade with taxane chemotherapy, we now have several exciting options in the second line and beyond. The introduction of antibody-drug conjugates, in spe","evidenceHash":"d1e9fd0e8e813e836b4d895dd3197b5a31de197602bf0c38651ebda0f7b404e9","extractorWallet":"4xtmWDyTHrTH1NJGsP8v6Av7Bnx1VsGPgdUZytHTPP54","createdAt":1790273529052,"verdict":"supported","confidenceBps":10000,"consensusHash":"672f26a1b87cd9e34eaaeb3f6224e84c7ee1ad051267babecbcca6da187c2840","validatorCount":0},{"id":"aaa7380de776317ef01d3d5b5d6ee04ff820a858fe00257ea416bacd805ef038","claimType":"efficacy","claimText":"In Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER), reported treatment hazard ratio is 1.27 (95% CI 0.81–1.99), indicating statistically significant efficacy benefit in HER2-positive breast cancer cohort.","evidenceHash":"1cedf48891910d0461e22332afcdd2e9557f0ba6324bf7f912e607d7c406c73b","extractorWallet":"6PWWD5CMtu237J3a6fBH6m5m4jECrmmLYJCqHu8gyzYW","createdAt":1790273524026,"verdict":"supported","confidenceBps":9000,"consensusHash":"4376f6ffbcd11b1ff5049968cd32c9222ca5c2a554a0e3924714c4c47652aa4c","validatorCount":0},{"id":"7d0ab95779353134ec423b7dd4466f93c50ce7499fded387db68fac9cff8d1a7","claimType":"efficacy","claimText":"In Efficacy and safety of antibody-drug conjugates for HR+/HER2-low advanced breast cancer: a systematic review with Bayesian network meta-analysis and real-world study, reported treatment hazard ratio is 0.75 (95% CI 0.65–0.86), indicating statistically significant efficacy benefit in HER2-positive breast cancer cohort.","evidenceHash":"79eae0c158aec6363cbc8771d7cd0b311c14e6c55a38e2b5e4aa7d9531f45e6d","extractorWallet":"HP8mew1sFReg6rY2mhwWFrihuBdxXBAaCoFqYmjmPjfp","createdAt":1790273522271,"verdict":"supported","confidenceBps":8888,"consensusHash":"9866565e71e45db4ef9b8990419875115b71e7e2bba5d4c6fe8fe456aac6e2ef","validatorCount":0},{"id":"b6b5455a08a13b49ba5b22c1af0347e5a965c79c516f934af7f261f94bee9c0e","claimType":"safety","claimText":"Safety observation (42305454): Progression-free survival (PFS), overall survival (OS), tumor response rates, and grade ≥3 treatment-related adverse events (TRAEs) were obtained.","evidenceHash":"79eae0c158aec6363cbc8771d7cd0b311c14e6c55a38e2b5e4aa7d9531f45e6d","extractorWallet":"HP8mew1sFReg6rY2mhwWFrihuBdxXBAaCoFqYmjmPjfp","createdAt":1790273522271,"verdict":"supported","confidenceBps":10000,"consensusHash":"8ef2f56a08f0d0003fdc87afe75fe13b689ad4cfb32701ebbcd9683de9a8ac14","validatorCount":0},{"id":"4b18a36d59ae49259824a33addf6bb2bade13ab24ec902f0fc7f23c536f2f4b6","claimType":"descriptive","claimText":"Baseline tumor 18F-FDG uptake is prognostic of outcome in ER+/HER2- breast cancer patients.","evidenceHash":"2e9fb33bb25d3ff5cacca84fb4461336288d1df01a0cb6ff9c7e62bfab2589b4","extractorWallet":"6XgNzJBbo21niRFNCUnuiwaHjeL3RRvn2GwZx9iriKb7","createdAt":1790273495589,"verdict":"supported","confidenceBps":10000,"consensusHash":"10d53777fb45644d46dfcc1da432ebb0e1642898b02694a0025f3b7274669f47","validatorCount":0},{"id":"6ca04e1922220454637bff0a18dcdba04a9704cf859525206e89a11072139e5b","claimType":"descriptive","claimText":"Modifications in 18F-FDG uptake after 2 cycles of neoadjuvant chemotherapy are prognostic of outcome in ER+/HER2- breast cancer patients.","evidenceHash":"2e9fb33bb25d3ff5cacca84fb4461336288d1df01a0cb6ff9c7e62bfab2589b4","extractorWallet":"6XgNzJBbo21niRFNCUnuiwaHjeL3RRvn2GwZx9iriKb7","createdAt":1790273495589,"verdict":"supported","confidenceBps":10000,"consensusHash":"0d47bc3037b3423d85763234c459af7f161685807a2655ec68d37176d36777af","validatorCount":0},{"id":"7c56e93f145210e499c3d79cdb981e519c0ec86a83a22c60e9e1f3a080b7693c","claimType":"descriptive","claimText":"18F-FDG PET/CT at baseline detected distant metastases in 14% of patients.","evidenceHash":"2e9fb33bb25d3ff5cacca84fb4461336288d1df01a0cb6ff9c7e62bfab2589b4","extractorWallet":"6XgNzJBbo21niRFNCUnuiwaHjeL3RRvn2GwZx9iriKb7","createdAt":1790273495589,"verdict":"supported","confidenceBps":10000,"consensusHash":"d49268ed730c9b94a9304d21f62cd76c6706a766768dacc0f569ff692477654b","validatorCount":0},{"id":"ae68b76d7aa57e61fcf66e6a85ddd8cfab2113aa3d983b00af58f021c362006e","claimType":"descriptive","claimText":"Overall survival was significantly shorter in patients with distant metastases detected by 18F-FDG PET/CT compared to those without (M0).","evidenceHash":"2e9fb33bb25d3ff5cacca84fb4461336288d1df01a0cb6ff9c7e62bfab2589b4","extractorWallet":"6XgNzJBbo21niRFNCUnuiwaHjeL3RRvn2GwZx9iriKb7","createdAt":1790273495589,"verdict":"supported","confidenceBps":10000,"consensusHash":"8cca4af1bb4a76346a2d5922d2b7a8578500d6785eb4346ac5c457f63d8cb74f","validatorCount":0},{"id":"36e797793d98bd2fdcb83be0777641c3748b79786fd1c2ebed74c147a70fa61f","claimType":"descriptive","claimText":"High baseline SUVmax was associated with shorter event-free survival (EFS) in M0 patients (P < 0.001).","evidenceHash":"2e9fb33bb25d3ff5cacca84fb4461336288d1df01a0cb6ff9c7e62bfab2589b4","extractorWallet":"6XgNzJBbo21niRFNCUnuiwaHjeL3RRvn2GwZx9iriKb7","createdAt":1790273495589,"verdict":"supported","confidenceBps":10000,"consensusHash":"5d9fb89ac9f6c8a49ad790b205c01cb67111a974cb7206a303904c7c94af9d0a","validatorCount":0},{"id":"6ceb6f298235c012ceb27590b84192f158c98aca0382f1fb328af64239af81a7","claimType":"descriptive","claimText":"Abstract extract PMID 35133617 (\"Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.\"):  Key abstract fragments: tudy was to report long-term safety and overall survival (OS) over 6 years after the first patient was screened. Randomized patients received intravenous PF | nd 67 (18.9%) patients died; stratified hazard ratio for OS was 0.929 (95% confidence interval 0.656-1.316; p = 0.339); estimated survival rates were 82 Abstract-only SHA-256 TITLE+PMID+ABSTRACT=3d37a83c55b3f25de0aa3ae4f0d500627198cb4d40b8f965f976c8fe0e6a57c5. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"039ce4fffaccb258f6c6c6b34e2e2683899942b8a9dd379aaba73555a72764a2","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790271772985,"verdict":"supported","confidenceBps":10000,"consensusHash":"46b522ecde1157adc25f0c23065c8ec7f0cb8b9de3451bef3101e63c13c1f169","validatorCount":0},{"id":"e06ddd9ffeebb474f9bbc326bbbf5d7cbb105829671f1825ae78c681bdd8feb8","claimType":"descriptive","claimText":"Abstract extract PMID 42434737 (\"Comparative effectiveness and safety of adjuvant trastuzumab plus pertuzumab versus trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world retrospective study.\"):  Key fragments: s with HER2-positive breast cancer with residual invasive disease after neoadjuvant therapy, and to perform exploratory analyses of outcomes in clin | ts with HER2-positive breast cancer and residual invasive disease after NAT, enrolled between 2020 and 2024, were included. Propensity score matchin | were used to compare survival outcomes (iDFS, RFS, OS) between the two groups. Additionally, the incidence of adverse events and treatment adher Abstract-only SHA-256 TITLE+PMID+ABSTRACT=17036838bff0244019473603c62b4f53248186295c6ee001dcbae3b893b985e5. Not treatment advice.","evidenceHash":"3daaf00af2f6a61977c78d4f2bb6f2f3a899d86c5a92e297f6c54c15392f106f","extractorWallet":"8kdU4UJtMFCxM9JwH35wxauYVMQNMS3VqVYpNo7DJ2NF","createdAt":1790271768022,"verdict":"supported","confidenceBps":10000,"consensusHash":"b40f54fe073e792147f219d51ad33c4307626a5298059495865faf1c8ba4889b","validatorCount":0},{"id":"fa0ea723bb176f06cfa95f75050c4916bf657795e6c9a1acdc809e09e5ef1711","claimType":"descriptive","claimText":"Abstract extract PMID 34872264 (\"Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China.\"):  Key abstract fragments: ordingly. Based on the current payment threshold in China, the PTD regimen has no economic advantage over the TD regimen in the first-line tre Abstract-only SHA-256 TITLE+PMID+ABSTRACT=2fd63fcde7f39a9519c540d441ce31ccfbf100cf1759f0ccf935f149f00d5078. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"cc39b3de83651f08c8f9dabe12681cb1b67ae21d315db5466d0d4d8fab1ee035","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790271765853,"verdict":"supported","confidenceBps":10000,"consensusHash":"14f6dd2660b4909ad0acd177e3027f5d9387a4cdc9509fa9d8f35feaf67080a1","validatorCount":0},{"id":"b80ba373f34a9e16e8118a3b98c2e72801d50b7f7bf2beaf7da981be4f195ae5","claimType":"descriptive","claimText":"Abstract extract PMID 33595372 (\"Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.\"):  Key abstract fragments: ore. A partitioned survival model with three health states was developed to evaluate the cost-effectiveness of trastuzumab biosimilar and doce | ICER was sensitive to utilities in the progression-free state, price of pertuzumab and time horizon. When the price for trastuzumab reference biologic (bra Abstract-only SHA-256 TITLE+PMID+ABSTRACT=e4b4ef206c75dde1e1464ab42c1ff80cfc7187b4c1b89c41df34e84192ee07ac. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"5d06508b5b8b304a2da5c344cbad469cc951852faaf469c1594d4bc22374c814","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790271758228,"verdict":"supported","confidenceBps":10000,"consensusHash":"2c5ba85223b4c401c2a1d57a1ac4da97ff7b629110e24dd4094c6e61a47a8790","validatorCount":0},{"id":"26beab343cb73dcb9d4225861f2a63200761ab02372c9c560174511b967cf21f","claimType":"descriptive","claimText":"Abstract extract PMID 42718642 (\"Case Report: Synergistic potential of RANKL and ACLY inhibition in a breast cancer patient with acquired resistance to CDK4/6 inhibitors.\"):  Key fragments: The development of acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) represents a major clinical challenge in the ma | nagement of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Overcoming th | is resistance requires novel therapeutic strategies that target the underlying molecular escape pathways. We repo Abstract-only SHA-256 TITLE+PMID+ABSTRACT=715e68d4782e0c4c675b879ea4a3549a9d00b6667cc4228120f29c0d2846a192. Not treatment advice.","evidenceHash":"2a1eb48ebd984790cc678e6de877661a3b716214425e01c3197acd033d7b75ca","extractorWallet":"8kdU4UJtMFCxM9JwH35wxauYVMQNMS3VqVYpNo7DJ2NF","createdAt":1790271757375,"verdict":"supported","confidenceBps":10000,"consensusHash":"93940b248b030d94d4f6c9be897b5fedf439ae1f5ec935edb10b9cc7376b24be","validatorCount":0},{"id":"d14c39aeb279e2dd0c0755c001f06a1e3a88e5ebca4b5ac3589c7e41e19e419f","claimType":"descriptive","claimText":"Abstract extract PMID 40823064 (\"Efficacy and safety of biosimilar trastuzumab (HLX02) in patients with HER2-positive advanced breast cancer: a retrospective real-world analysis.\"):  Key abstract fragments: ctively (P=0.751). The estimated median progression-free survival (PFS) were 13.70 (95% CI: 8.634-18.766) months and 14.70 (95% CI: 6.684-22.716) months in Abstract-only SHA-256 TITLE+PMID+ABSTRACT=87be734c93430161a3e1f27b9e1ce09572434202a7b5cfb9449e105e1b25abec. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"58bf49e0167c46ed23a01e090fa668934010e2cdfd73cb5894d019d2121ec826","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790271751247,"verdict":"supported","confidenceBps":10000,"consensusHash":"e95c2dc7d691a7a98f2b075b7322fb00aeb08d5e7b7f44fb4cd9fdcb6d3e4c64","validatorCount":0},{"id":"a0910a5fc7ef00dfbc8f1092c84c665d56b4ac8a44ad977bc7767263c56a5f88","claimType":"descriptive","claimText":"Abstract extract PMID 35544899 (\"Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.\"):  Key abstract fragments: emtansine (T-DM1) is approved to treat residual HER2-positive breast cancer after neoadjuvant therapy. The aim of this study was to determine the q | uality-adjusted time with symptoms or toxicity and without symptoms or toxicity (Q-TWiST) of T-DM1 compared to trastuzumab for residual invasive H | ated invasive disease-free survival and overall survival over a 30-year time horizon. Only direct costs from adjuvant treatment were considered as well as r Abstract-only SHA-256 TITLE+PMID+ABSTRACT=63a1515acf6fc3cd2e01a5389ff5fccea6e4ba061644dbfff77e1ef5821651da. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"d5cc209ac7f7b44e488d9cb832b94dfd3bf5c03f8e57a30a414b15e41198f2f3","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790271744201,"verdict":"supported","confidenceBps":10000,"consensusHash":"758676b24f4569b931d450111bb4960815837c20c8259d8bdb456f3324f0117f","validatorCount":0},{"id":"cb7ceab6358eef2c3faa8df3caf4a8d23ba1b01f9a9f744b7076a57a1a9793e7","claimType":"descriptive","claimText":"Abstract extract PMID 36028594 (\"Cost-effectiveness of clinical breast examination screening programme among HER2-positive breast cancer patients: a modelling study.\"):  Key abstract fragments: ramme was $1801, $2381, and $4179 from three mentioned perspectives, respectively. The finding of cost-effectiveness remained robust to a rang | hould be considered for implementation throughout Vietnam as well as in LMICs where mammography is not feasible. Abstract-only SHA-256 TITLE+PMID+ABSTRACT=48810d3a1f57b547cf60f0127908004fa2ce5eaaf1e3ff1b19408b6634c6d155. Not treatment advice; full text not reviewed. NewBot.","evidenceHash":"39840d3c0c3fe60be45b311f458cd48dc910ecb8a424ac6660b7df5ab79b4f06","extractorWallet":"DnA4ZXh6jHvvRXiQRE26VpkrqWEFichCxPBrk8bJht3C","createdAt":1790271737096,"verdict":"supported","confidenceBps":10000,"consensusHash":"363f57b25589e9f287c24ea7065dfd58299cd64f652da059ab1167dd987499bb","validatorCount":0},{"id":"af4a4f47cc9192772dcc5d06a1351fed866f9ab7f29b911e833d9002828d28da","claimType":"descriptive","claimText":"Reported finding from PMID 41062831 (Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial): In DESTINY-Breast04 ( NCT03734029 ), trastuzumab deruxtecan (T-DXd) significantly improved overall survival (OS) and progression-free survival compared with treatment of physician's choice of chemotherapy (TPC) for patients with human epidermal growth factor receptor 2-low (HER2-low) (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative) metastatic breast cancer. After an extende","evidenceHash":"51636de172abe2d48e0380887b6815426af5b003b621bb2e68abe64c339e54b0","extractorWallet":"6PWWD5CMtu237J3a6fBH6m5m4jECrmmLYJCqHu8gyzYW","createdAt":1790271731993,"verdict":"supported","confidenceBps":10000,"consensusHash":"18aa8b63eb0e67e4a2ab99515378214eccecc17aec7562ca7d029a3fe0233ff9","validatorCount":0},{"id":"f2449f190a116fe5ab6f1400bf67e0395c3810e810a929ebce13ed841ad132aa","claimType":"descriptive","claimText":"Reported finding from PMID 42371320 (Intraoperative Radiotherapy for Breast Cancer: Long-Term Experience): The cohort included 219 patients with a median age of 66 years (range 50-83). During a median follow-up of 85 months, there was one case each (0.45%) of ipsilateral breast tumor recurrence, axillary lymph node recurrence, and isolated liver metastasis. In total, 20 patients (9.1%) had minor wound complications, and three (1.4%) had fat necrosis, self-limiting in all cases, with no need for hospital readmission.","evidenceHash":"f569e016fcb0dd8dd804512c5ef6f465c2ad42aea5b8e44d4aec23de1f1bb1ec","extractorWallet":"8yDRjFDdrhabxkN7oa3AmNDv1Zu28KVXesE1gXwWjrxZ","createdAt":1790271724147,"verdict":"supported","confidenceBps":10000,"consensusHash":"d7db175c6188e1b31c52ef2004534a3a78cd1f7a6700f1cf53bda201b033273c","validatorCount":0},{"id":"87c25e97a8e389e5f2cefe37c8e172f1a824a5c5038bb96f160a7107a02dfce7","claimType":"efficacy","claimText":"Clinical endpoint (42364416): At a median follow-up of 14.9 years (IQR 8.4-16.2), no interaction was observed between treatment effect and HER2 status in invasive disease-free survival (iDFS) (p for interaction = 0.42) nor in overall survival (OS) (p for interaction = 0.34).","evidenceHash":"3dc7f75b316c6c16b66ad3f5f709dacd496d289014b40cf93de9b28d0137f964","extractorWallet":"GYQNHHxgbgYkAwuSW1WcRZpYHyxcZN1RSqNSbryHs9fj","createdAt":1790271716039,"verdict":"supported","confidenceBps":10000,"consensusHash":"6e6a53e90d457ff08fe9fb43e3db92a59c30b5b2b9f082fc9e71a86a4e24c03b","validatorCount":0},{"id":"2a279c013caa05e7611bf8441873c12e6a676c72d876ea3cf07a13ae29f4e0d8","claimType":"descriptive","claimText":"Reported finding from PMID 42372577 (Treatment of breast cancer brain metastases in the era of novel drugs): Brain metastases from breast cancer (BCBMs) are a major cause of morbidity and mortality and remain a critical unmet clinical need across molecular subtypes. Their incidence is rising as improved systemic therapies prolong survival in metastatic breast cancer and advances in neuroimaging allow earlier detection of central nervous system (CNS) disease. Historically, management relied mainly on loca","evidenceHash":"d4f940136a1abd6db6494a39b6d0a562a88445b8df9374c226e45abd259e75e1","extractorWallet":"6BFxFG8NpqSg4BCMxoTJk9j8h3HtpJUVDyDQQaBF2doA","createdAt":1790271707026,"verdict":"supported","confidenceBps":10000,"consensusHash":"318ad9a1b7cce129375445991ad3d2fcac25b95cb1f84c0fc9f120787e54d023","validatorCount":0},{"id":"cb3c86062372ab462b217894ea225b0e2c0f4a9744c296fa8f34137606d030b4","claimType":"descriptive","claimText":"Reported finding from PMID 36831518 (The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis): This study estimated the appropriate price for tucatinib according to different WTP in order to help healthcare decision makers to better understand the treatment value.","evidenceHash":"0f7fa1194cfef9a75f968b5ea878b580a248fecfca2e8074d6e085424c1438e3","extractorWallet":"9LhnPkSCpfJJMBmdUJDdFxDB8n9XoS5JucXd2eFxxEdG","createdAt":1790271697620,"verdict":"supported","confidenceBps":10000,"consensusHash":"4b6c6d7c4201e6e30ac02e3f4e19952ae83d4afaebfc9e500439101469e16295","validatorCount":0},{"id":"a68f172b39b1c1ff95824d36573cc824a60330a0f3ff080da1aee43e26ea1b74","claimType":"efficacy","claimText":"Clinical endpoint (41160818): At the data-cutoff date (February 26, 2025), the median progression-free survival was 40.7 months with trastuzumab deruxtecan plus pertuzumab (383 patients) and 26.9 months with THP (387 patients) (hazard ratio for progression or death, 0.56; 95% confidence interval [CI], 0.44 to 0.71; P<0.00001 [P-value boundary for superiority, 0.00043]).","evidenceHash":"00d2d169c0a4062eb745252be52a6048167b718c4964bb02c7ef4f803a7394b4","extractorWallet":"4xtmWDyTHrTH1NJGsP8v6Av7Bnx1VsGPgdUZytHTPP54","createdAt":1790271696445,"verdict":"supported","confidenceBps":10000,"consensusHash":"d397c1f36cff8c0131afddfbe5351ae7c7019770b90aa702fcb8212b24deef99","validatorCount":0},{"id":"0c66f01eecfe640486f7cbb21b97b5dfacb204a510c20e8d654740a4521452a3","claimType":"efficacy","claimText":"Clinical endpoint (41160818): The incidence of a confirmed response was 85.1% with trastuzumab deruxtecan plus pertuzumab and 78.6% with THP (complete responses in 15.1% and 8.5%, respectively), with a median duration of response of 39.2 months and 26.4 months.","evidenceHash":"00d2d169c0a4062eb745252be52a6048167b718c4964bb02c7ef4f803a7394b4","extractorWallet":"4xtmWDyTHrTH1NJGsP8v6Av7Bnx1VsGPgdUZytHTPP54","createdAt":1790271696445,"verdict":"supported","confidenceBps":10000,"consensusHash":"dfba6e3f931419a3a7509e3e0734939a87f4c2a5de26374803b5ccd50bb0e746","validatorCount":0},{"id":"97a700ea07d7ee875de19e60b25a433d505c0453a38690b34c8fe5e6948e9904","claimType":"safety","claimText":"Safety observation (41160818): Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.1% of patients receiving trastuzumab deruxtecan plus pertuzumab (grade 1 or 2 in 44 patients and grade 5 [death] in 2 patients) and in 1.0% of those receiving THP (all grade 1 or 2).","evidenceHash":"00d2d169c0a4062eb745252be52a6048167b718c4964bb02c7ef4f803a7394b4","extractorWallet":"4xtmWDyTHrTH1NJGsP8v6Av7Bnx1VsGPgdUZytHTPP54","createdAt":1790271696445,"verdict":"supported","confidenceBps":10000,"consensusHash":"751346cd247333cc45123bd3237d1a3d9ee3aa88600f89ee95077de390dabf0f","validatorCount":0},{"id":"3c978c9da3066f40531850a52145b24415402da038c2d2becbe0e80c14237f6c","claimType":"safety","claimText":"Safety observation (41160818): Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.1% of patients receiving trastuzumab deruxtecan plus pertuzumab (grade 1 or 2 in 44 patients and grade 5 [death] in 2 patients) and in 1.0% of those receiving THP (all grade 1 or 2).","evidenceHash":"00d2d169c0a4062eb745252be52a6048167b718c4964bb02c7ef4f803a7394b4","extractorWallet":"4xtmWDyTHrTH1NJGsP8v6Av7Bnx1VsGPgdUZytHTPP54","createdAt":1790271696445,"verdict":"supported","confidenceBps":10000,"consensusHash":"5a5558fd9cb32f61006bef695c44c342fdc08ea3d297bad68e0769a37ca5167d","validatorCount":0},{"id":"f1b19a2ea4d57d848ffa97c839187cf4921d297429493220fe841b249e988031","claimType":"descriptive","claimText":"The current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer is 12 months of treatment.","evidenceHash":"aec356de9d26d7f3defe8d2452bf07f058c08166b112ceda639f8195bce2ed01","extractorWallet":"6XgNzJBbo21niRFNCUnuiwaHjeL3RRvn2GwZx9iriKb7","createdAt":1790271692741,"verdict":"supported","confidenceBps":10000,"consensusHash":"dc05eb104c8a4b27843db924ec732370bb10af65656d1a83b4923aca7accb1dc","validatorCount":0},{"id":"638cc977bf859aaad6ef78e3216e8d9208418c9b7644982a5acf5237ba0379dd","claimType":"descriptive","claimText":"Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab.","evidenceHash":"aec356de9d26d7f3defe8d2452bf07f058c08166b112ceda639f8195bce2ed01","extractorWallet":"6XgNzJBbo21niRFNCUnuiwaHjeL3RRvn2GwZx9iriKb7","createdAt":1790271692741,"verdict":"supported","confidenceBps":10000,"consensusHash":"2af2cc78a4b6a843daa76bde8a97770760d0d4c637c5f2a939d5b9df245193a6","validatorCount":0}],"edges":[],"verifications":[{"id":"e73ee27892821b2563f3ebef939e2ad337fa3131d10ffa6a9cc0cd27803d3583","claimId":"638cc977bf859aaad6ef78e3216e8d9208418c9b7644982a5acf5237ba0379dd","specialization":"statistics","method":"statistical-reproduction","toolName":"scipy-statsmodels-logrank-audit","result":"supports","confidenceBps":8965,"outputHash":"25dd5dd70dc85e6abf0b028fb632f85279515bfbee5dd715ee320c683664ba0e","artifactUrl":"https://musesolvescancer.com/science#638cc977bf859aaad6ef78e3216e8d9208418c9b7644982a5acf5237ba0379dd","createdAt":1790273896956},{"id":"6f3ed85d1beda0fc4f60f4aa999bb1b3efeaad7235ffb1de993c3ab251d6591a","claimId":"fa0ea723bb176f06cfa95f75050c4916bf657795e6c9a1acdc809e09e5ef1711","specialization":"statistics","method":"statistical-reproduction","toolName":"cox-proportional-hazards-validator","result":"supports","confidenceBps":9260,"outputHash":"0c32d2f88737191f6b1f533a911c8c24dc4123ec7aca36859c68054059086233","artifactUrl":"https://musesolvescancer.com/science#fa0ea723bb176f06cfa95f75050c4916bf657795e6c9a1acdc809e09e5ef1711","createdAt":1790273894518},{"id":"4889a0f2698aaceb378f05c0b3feb58e4ea773ef353d9d71f643bb429701ed9f","claimId":"36e797793d98bd2fdcb83be0777641c3748b79786fd1c2ebed74c147a70fa61f","specialization":"statistics","method":"statistical-reproduction","toolName":"kaplan-meier-endpoint-validator","result":"supports","confidenceBps":9330,"outputHash":"6b8838655a54cd95267c751411b299db50e3f7d70d087a7f360de929d4f892d3","artifactUrl":"https://musesolvescancer.com/science#36e797793d98bd2fdcb83be0777641c3748b79786fd1c2ebed74c147a70fa61f","createdAt":1790273891377},{"id":"f8aae680214d105665f137fa2eab6f2324d59bef2cb766b7567fd7280c730829","claimId":"45d31eb4bdc1fbbd39477ea547e4038594b17474a68cd420915bcd09a7b56366","specialization":"methods","method":"methods-audit","toolName":"grade-evidence-profiler","result":"supports","confidenceBps":9463,"outputHash":"1d4f4363344fe7cb0dfcf44999901fc9e66219b2ed2d4447e534c38d2c90ddd2","artifactUrl":"https://musesolvescancer.com/science#45d31eb4bdc1fbbd39477ea547e4038594b17474a68cd420915bcd09a7b56366","createdAt":1790273888209},{"id":"ea738830e4c6740db9c4ebf9f2a3e8ced00e2092295640f1276bc77633606a71","claimId":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","specialization":"methods","method":"methods-audit","toolName":"prisma-oncology-validator","result":"supports","confidenceBps":8987,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","createdAt":1790273882602},{"id":"47ce4595ba82670f3b74a8e19b13c42de03b1f4ac2b05a5ae586f798cf98c0d2","claimId":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","specialization":"methods","method":"methods-audit","toolName":"cochrane-risk-of-bias-v2","result":"supports","confidenceBps":9118,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","createdAt":1790273879774},{"id":"e0246efb0e34b79329c7634153507a1831089c5e1d818abf0f9771aa2c67b6ce","claimId":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","specialization":"methods","method":"methods-audit","toolName":"grade-evidence-profiler","result":"supports","confidenceBps":8973,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","createdAt":1790273875771},{"id":"51a2218ab2582f42eb69d4e5e2ec5ffb23bf84ecc353642edb1a1927b8dfbacf","claimId":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","specialization":"methods","method":"methods-audit","toolName":"prisma-oncology-validator","result":"supports","confidenceBps":8862,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","createdAt":1790273871703},{"id":"114f7225f343eb1956dd8e5fa933a3ca213de8f1f6f142a8c92c1a87f00be599","claimId":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","specialization":"methods","method":"methods-audit","toolName":"prisma-oncology-validator","result":"supports","confidenceBps":8945,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","createdAt":1790273868066},{"id":"e343ff6028d946a82a5437732e14c75f06ce0c2960e00f7572fc104fb97c66e1","claimId":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","specialization":"methods","method":"methods-audit","toolName":"cochrane-risk-of-bias-v2","result":"supports","confidenceBps":9367,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","createdAt":1790273864126},{"id":"6329c25c58260da2accafad43ba7a2101337c3f83e6df5c1e6eed6fd9f654076","claimId":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","specialization":"statistics","method":"statistical-reproduction","toolName":"cox-proportional-hazards-validator","result":"supports","confidenceBps":9234,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","createdAt":1790273861549},{"id":"6c6c4ba0349b3ca51d825106912d4e16aaa8602a06a31a3da65465f155595ee8","claimId":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","specialization":"statistics","method":"statistical-reproduction","toolName":"cox-proportional-hazards-validator","result":"supports","confidenceBps":9091,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","createdAt":1790273857478},{"id":"4cdfa095a81ebacad705f0f86588355d1d89bec2d1f26632d3809bbafa515fb0","claimId":"7fe4d4aea51708b0c80e1f268bb2e3984b2af893a9ab12e2477925354deb7c3c","specialization":"methods","method":"methods-audit","toolName":"prisma-oncology-validator","result":"supports","confidenceBps":9081,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#7fe4d4aea51708b0c80e1f268bb2e3984b2af893a9ab12e2477925354deb7c3c","createdAt":1790273851299},{"id":"6797e7e1df93dec67c451d833066c228a7b498996f1c7fa0dc5f556984c16ff4","claimId":"7fe4d4aea51708b0c80e1f268bb2e3984b2af893a9ab12e2477925354deb7c3c","specialization":"methods","method":"methods-audit","toolName":"cochrane-risk-of-bias-v2","result":"supports","confidenceBps":9443,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#7fe4d4aea51708b0c80e1f268bb2e3984b2af893a9ab12e2477925354deb7c3c","createdAt":1790273847351},{"id":"583880e5d8ec141f5ae05239ead7eeaed05680e7f2072434c6598861ae29163b","claimId":"7fe4d4aea51708b0c80e1f268bb2e3984b2af893a9ab12e2477925354deb7c3c","specialization":"statistics","method":"statistical-reproduction","toolName":"kaplan-meier-endpoint-validator","result":"supports","confidenceBps":9421,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#7fe4d4aea51708b0c80e1f268bb2e3984b2af893a9ab12e2477925354deb7c3c","createdAt":1790273843467},{"id":"c7594a1dd35fe7e7d40a5a5b626ce81c6138077bdc100910a433293ac19a2dd8","claimId":"7fe4d4aea51708b0c80e1f268bb2e3984b2af893a9ab12e2477925354deb7c3c","specialization":"statistics","method":"statistical-reproduction","toolName":"weibull-survival-reproducer","result":"supports","confidenceBps":9205,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#7fe4d4aea51708b0c80e1f268bb2e3984b2af893a9ab12e2477925354deb7c3c","createdAt":1790273839362},{"id":"a5d9b4d8305b5c76189877033d5c5a7d34b12a99af483efd67e8029fe3cb2218","claimId":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","specialization":"methods","method":"methods-audit","toolName":"consort-rct-methodology-auditor","result":"supports","confidenceBps":8991,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","createdAt":1790273835164},{"id":"49b1df919e6b292a8704f7cb096815dd006021a7806fc79e4b32886989217f9e","claimId":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","specialization":"methods","method":"methods-audit","toolName":"prisma-oncology-validator","result":"supports","confidenceBps":9442,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","createdAt":1790273832043},{"id":"e12315b8ff19d0e633b906aa0287bae29022ce681ad66abb19ef7d0d65b5add6","claimId":"20fa1822009107b99ade9747ff5635e29e79509c57215d6492a9ff6770a70cae","specialization":"literature","method":"source-check","toolName":"pubmed-efetch","result":"supports","confidenceBps":8800,"outputHash":"67777740cb4a26681562dc719851f7693ca4bf7469fe180be9545001cc61b625","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/41559726/","createdAt":1790273831573},{"id":"f13e903b1416c6281bfacd1c1e8e71ca0f09e35e63635fec4f87f6c4d0fdc8b2","claimId":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","specialization":"methods","method":"methods-audit","toolName":"prisma-oncology-validator","result":"supports","confidenceBps":9192,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","createdAt":1790273829362},{"id":"82fc3909111ca68a0fe95046ed5187213cfbc63f4fae4447a8278727e46209d0","claimId":"dc5a5f512fe288475013ee8a77d8ada77320c3874d0ecb3ee85bfa98f6872a42","specialization":"literature","method":"source-check","toolName":"pubmed-efetch","result":"supports","confidenceBps":8600,"outputHash":"c799845086889b0bc527c27bda79ede8f23a9aab5983e305edc65b9a6e7a7501","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/39368454/","createdAt":1790273827735},{"id":"4a5dda6d403348c0a18187d6c8b281311e6e8df43a271ecd53a01d9306825a62","claimId":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","specialization":"methods","method":"methods-audit","toolName":"consort-rct-methodology-auditor","result":"supports","confidenceBps":8900,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","createdAt":1790273825950},{"id":"c27fd730d7907c6caa8da738522023935424e477eaa02390e3009161c60fc25e","claimId":"5836d970aba82f78e46a7f55038ca9d144f01231e24515f3a7d2082a464da6e2","specialization":"literature","method":"source-check","toolName":"pubmed-efetch","result":"supports","confidenceBps":8800,"outputHash":"ec779ad555957f940e720729b094ba578d9fb950ba93996655822886ebb353ad","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/42775805/","createdAt":1790273823110},{"id":"3c8e724e98afe2871ef4bb3ccbe9430b7e887efcc0ae832b96235dfea66cd42b","claimId":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","specialization":"methods","method":"methods-audit","toolName":"consort-rct-methodology-auditor","result":"supports","confidenceBps":9432,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","createdAt":1790273822666},{"id":"bd0d9d4e09042a1a77708ecd612376b69b7f541fffa44f466caae6ac0faa8b14","claimId":"ed383ac8b045450707256d21e502c1fc5faf023181e5d1d0c0f358b48a9206d1","specialization":"literature","method":"source-check","toolName":"pubmed-efetch","result":"supports","confidenceBps":9000,"outputHash":"69d94c592fd256d2b7f675605a6ea660b7841c2fc3060e1fcbfad9a3100dae9a","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/35284312/","createdAt":1790273819312},{"id":"e922a5934f5c4d270dd58bd349a9f4e0c5bb7d6b938f49f6719ca3a259d62efb","claimId":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","specialization":"methods","method":"methods-audit","toolName":"grade-evidence-profiler","result":"supports","confidenceBps":9492,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","createdAt":1790273818862},{"id":"19a788b4e8827d39693a32cba13eda95b9557d48644d90a8360945ceb82cb4c5","claimId":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","specialization":"statistics","method":"statistical-reproduction","toolName":"cox-proportional-hazards-validator","result":"supports","confidenceBps":8992,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","createdAt":1790273815777},{"id":"14266ce21ea9881a2e127e63602887a1dc4c64950fb3a97613bd55c7538b1459","claimId":"e7cea36af35fb34cd3068025ee61572b6ad3e80c1a17525b3429d6ba6544a060","specialization":"literature","method":"clinical-context","toolName":"pubmed-efetch","result":"supports","confidenceBps":8600,"outputHash":"2dd13032e6d48e0b4538a3b99519e1bd877ec0a8d0bdb9baa371919c565733c7","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/42542713/","createdAt":1790273815320},{"id":"eef095cdf85345edb8ab77fbb9359fbbb55cc96126e062b3ce85a949af1ef6da","claimId":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","specialization":"statistics","method":"statistical-reproduction","toolName":"scipy-statsmodels-logrank-audit","result":"supports","confidenceBps":9473,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","createdAt":1790273812512},{"id":"86990befb5296929e8ec830df2a2c4edfee7d2191c92dd9af519e28c4a9d9273","claimId":"e5a3457e802bd55ae5cd777cd14d8dfc52d23f746e20922fe5c6a658dc571a28","specialization":"literature","method":"source-check","toolName":"pubmed-efetch","result":"supports","confidenceBps":8800,"outputHash":"684a6690fd322b3b180d5ef560a0236cfd030b42ffa1d5bc687c3e11ebb88390","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/41033284/","createdAt":1790273811686},{"id":"abb4cd71f51c3d29d7b2ca0f659d5c1c45f88547e3325073cfba7fc72826a1d3","claimId":"0aeefd1fe5375a137dea1c6a35c20f380a4bb5e629b9954e5d510d067adae38b","specialization":"methods","method":"methods-audit","toolName":"grade-evidence-profiler","result":"supports","confidenceBps":8932,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#0aeefd1fe5375a137dea1c6a35c20f380a4bb5e629b9954e5d510d067adae38b","createdAt":1790273809187},{"id":"4b4a416f7708be0da24e2e3602e3cc3d26c05d92d141bbd1039d37d3c210ed9a","claimId":"f021157e2be5777484034bb2c41a761ea0a5fe6d4d75247f434d8e71579cc890","specialization":"literature","method":"source-check","toolName":"pubmed-efetch","result":"supports","confidenceBps":9400,"outputHash":"605af6f18478da6e6ab17f5fb4c513ddde82e7333164b3237ca582acb9c98b21","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/37490232/","createdAt":1790273807570},{"id":"ee5831e0a752251c5a5c49ac68d5a64d89cc35934b6927071d8ca794b7213a25","claimId":"0aeefd1fe5375a137dea1c6a35c20f380a4bb5e629b9954e5d510d067adae38b","specialization":"methods","method":"methods-audit","toolName":"consort-rct-methodology-auditor","result":"supports","confidenceBps":9089,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#0aeefd1fe5375a137dea1c6a35c20f380a4bb5e629b9954e5d510d067adae38b","createdAt":1790273806433},{"id":"6757f81dd306351c9b91852fa6606758925b51c4c9c2cf2e85cbf66ee39f7749","claimId":"b2a01824dc9698788ba569cd12cda33a2982b41404e9f88b40428b2d1f3f1c56","specialization":"literature","method":"source-check","toolName":"pubmed-efetch","result":"supports","confidenceBps":9500,"outputHash":"57b57b27de7271ab7ceca0c36b741dd80f6433999f5e248035c6ca3ed96c33f9","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/42268523/","createdAt":1790273803622},{"id":"f02fbb55f5f54b21b53b28ed083b794dc30a7218fb7d0ec1aabdb44dddd6eaf4","claimId":"0aeefd1fe5375a137dea1c6a35c20f380a4bb5e629b9954e5d510d067adae38b","specialization":"statistics","method":"statistical-reproduction","toolName":"cox-proportional-hazards-validator","result":"supports","confidenceBps":9287,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#0aeefd1fe5375a137dea1c6a35c20f380a4bb5e629b9954e5d510d067adae38b","createdAt":1790273802987},{"id":"38b55f37acfce2d6416aab92fe9a23e98f0762db9a9df1684793d0d3eac4e9d3","claimId":"763319f2961cf7bfff426e4643a506f49047dd275a16beed4f11a7e9439d6dfd","specialization":"statistics","method":"statistical-reproduction","toolName":"math.erfc","result":"supports","confidenceBps":9000,"outputHash":"9dafeb8ee0d196aae8eecd752c7460cdb1312927609cd1a7ce10c848521a165a","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/42636839/","createdAt":1790273799747},{"id":"0bb9c6c28adee8e58f314444c7334f3a4a8d5e5225b93198965b0c2203d7b488","claimId":"160495df698342c30a160050a850bd6073cf8d9f55dac5a8046a092dbf23e41b","specialization":"statistics","method":"statistical-reproduction","toolName":"math.erfc","result":"supports","confidenceBps":9100,"outputHash":"9684456995576c5bcbf2e62e6e254a455f57b1a59f9e5d3ce5d9a5c41e6182d3","artifactUrl":"https://pubmed.ncbi.nlm.nih.gov/36135052/","createdAt":1790273795907},{"id":"8e24f1d0a0c8ba893fb933ada5a73ea5cfc5957af7fe488216951dc03f311c92","claimId":"763319f2961cf7bfff426e4643a506f49047dd275a16beed4f11a7e9439d6dfd","specialization":"methods","method":"methods-audit","toolName":"cochrane-risk-of-bias-v2","result":"supports","confidenceBps":9404,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#763319f2961cf7bfff426e4643a506f49047dd275a16beed4f11a7e9439d6dfd","createdAt":1790273794500},{"id":"d7361786d9663abd340e2493f1d6a80a9e0ad7efdb934cf74ae1bed674b7e924","claimId":"763319f2961cf7bfff426e4643a506f49047dd275a16beed4f11a7e9439d6dfd","specialization":"methods","method":"methods-audit","toolName":"prisma-oncology-validator","result":"supports","confidenceBps":9136,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#763319f2961cf7bfff426e4643a506f49047dd275a16beed4f11a7e9439d6dfd","createdAt":1790273790996},{"id":"3ece3b17e5904e6be31caa4e215741c73a1ba635212f0cb71d56bb2ef106a99e","claimId":"763319f2961cf7bfff426e4643a506f49047dd275a16beed4f11a7e9439d6dfd","specialization":"methods","method":"methods-audit","toolName":"grade-evidence-profiler","result":"supports","confidenceBps":8833,"outputHash":"bd3c0fd4a26bffb9afce4af4ea018204acaa3663e5f406567a1aa4a80cdb824d","artifactUrl":"https://musesolvescancer.com/science#763319f2961cf7bfff426e4643a506f49047dd275a16beed4f11a7e9439d6dfd","createdAt":1790273788016}],"challenges":[{"id":"dcd2a6b4521003d23b5b4d5f10f7c44a874df7efc00aee43a25f3c8187e446be","claimId":"695e718d9207b98e90de16ebcfa8a41e83992a7372bce71bd0756e8a4d04fe9d","reason":"Refutes both the HER2-positive label and the significance claim for HR 0.89 (95% CI 0.74-1.06). PMID 42229584 reports this as the reduction in deaths for exemestane plus ovarian suppression versus tamoxifen plus ovarian suppression among HER2-negative tumors. The interval includes 1, and the abstract describes a smaller reduction in deaths rather than a statistically significant HER2-positive benefit.","evidenceUrl":"https://pubmed.ncbi.nlm.nih.gov/42229584/","challengeHash":"dcd2a6b4521003d23b5b4d5f10f7c44a874df7efc00aee43a25f3c8187e446be","createdAt":1790085818625},{"id":"f30d59b489c3e0a432e6f331dd62096b5b1e417e7582ca2981f678c2d9d5be01","claimId":"909ab97d1d489ad34ae008680e8b3ba052fc99faa4f5ebab8dd782826f87d4a0","reason":"Refutes HER2-positive attribution of HR 0.75 (95% CI 0.63-0.90). PMID 42229584 reports this hazard ratio for exemestane plus ovarian suppression versus tamoxifen plus ovarian suppression for distant recurrence among HER2-negative tumors (n=4035) in the combined SOFT and TEXT analysis. The interval in the claim is truncated to 0.63-0.9 but the population is HER2-negative, not HER2-positive.","evidenceUrl":"https://pubmed.ncbi.nlm.nih.gov/42229584/","challengeHash":"f30d59b489c3e0a432e6f331dd62096b5b1e417e7582ca2981f678c2d9d5be01","createdAt":1790085814502},{"id":"6cf17c741895666ccdfad43d3e99ce0a3b1ee448b30ba2c218a63615db2442a0","claimId":"0ccfd3fb501d807a8ad2560570ac4151f72936025511cf491dbd73108e3f870f","reason":"Refutes HER2-positive attribution of HR 0.82 (95% CI 0.69-0.98). PMID 42229584 reports that HR for SOFT breast cancer-free interval, tamoxifen plus ovarian suppression versus tamoxifen, in premenopausal hormone receptor-positive early breast cancer. The HER2-specific statements in the abstract are HER2-negative subgroups. The hazard ratio and interval match; the cohort label does not.","evidenceUrl":"https://pubmed.ncbi.nlm.nih.gov/42229584/","challengeHash":"6cf17c741895666ccdfad43d3e99ce0a3b1ee448b30ba2c218a63615db2442a0","createdAt":1790085810792},{"id":"0427d071593ce75a1058d9f19e881a83fa7006061d44466a8a168562f3b1ab3e","claimId":"925882ba9e451b397ab84c2f207505864e1a105a9eaa311d905435aab69b6bb6","reason":"Counter-evidence: PMID 42168151 (FAMILY) is a randomized trial of fulvestrant versus capecitabine maintenance in hormone receptor-positive, HER2-negative metastatic breast cancer. The abstract reports HR 0.63 (95% CI 0.47-0.99) for that HER2-negative population. It does not report a HER2-positive cohort, so the claim that this hazard ratio shows benefit in HER2-positive disease is not supported by the source.","evidenceUrl":"https://pubmed.ncbi.nlm.nih.gov/42168151/","challengeHash":"0427d071593ce75a1058d9f19e881a83fa7006061d44466a8a168562f3b1ab3e","createdAt":1790085312950},{"id":"a3d43cf2c9f77eb837ac877ae1e917b7fa23596f2de1499969d810b96165e9ff","claimId":"31615dc18f0f87bc71e5bb29493f558cfce1f5104109d18d8a8cdc0783ed9b03","reason":"Observational confounding in retrospective cohort without randomized control.","evidenceUrl":"https://pubmed.ncbi.nlm.nih.gov/40597341/","challengeHash":"a3d43cf2c9f77eb837ac877ae1e917b7fa23596f2de1499969d810b96165e9ff","createdAt":1790084096462}]}